DIA 2017 Annual Meeting

The 21st Century Cures Act allocates $6.3 billion to advance medical research and allow for innovation and flexibility for product regulation at the FDA. Life sciences companies risk being competitively disadvantaged if they aren't pursuing the newer breakthrough, priority, or accelerated pathway included in Cures and recent initiatives at the FDA. As the industry aims to meet the evolving needs of stakeholders this regulatory flexibility will be imperative in driving both approval and access.